Waters partners with Quest Diagnostics to expand access to at-home HPV screening
WAT•Waters will work with Quest Diagnostics to expand US access to its FDA-cleared Onclarity at-home HPV self-collection kit. Starting in 2027, Quest will offer access through clinician, health plan and consumer channels, with samples processed at its labs.
1. Access through Quest
Waters entered a collaboration with Quest Diagnostics to expand US access to the Onclarity at-home HPV self-collection kit, which is FDA-cleared. Starting in 2027, Quest will offer access through clinician, health plan and consumer channels.
2. Sample processing
Patients will be able to mail samples to Quest or drop them at approximately 2,000 patient service centers nationwide for laboratory processing. The collaboration leverages Quest’s reach to one in three American adults annually.
